Navigation Links
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Date:7/14/2010

e drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
2. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
3. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
4. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
5. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
6. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
7. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
8. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
9. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
11. AEterna Zentaris Announces Appointment of New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... and scale of EDS services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, ... million information technology (IT) services contract that,calls for EDS to ... scope and scale will allow the company to,improve productivity so ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE) announced today that ... of Finance and Chief Financial Officer., Jim Hitchin ... many years of,experience in public medical device, manufacturing and ... 25 years ago. With a graduate,degree in accounting, he ...
... Dec. 10 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that two,U.S. Patents, ... granted,to the Company by the United States Patent ... our on-going commitment to broadening,and protecting our intellectual ...
Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Jim Dorst Joins SpectraScience as CFO 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 45% on average over a 35 year period in ... the impact of humans on declining animal numbers. This ... as insects, spiders, crustaceans, slugs and worms bring to ... crops, decomposition for nutrient cycling, water filtration and human ... and led by UCL, Stanford and UCSB, focused on ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... working in College of Life Science, Zhejiang University, has ... CpG island has a parental differentially methylated region (DMR). ... imprinting exists in lower vertebrates and genomic imprinting should ... mammals. The study is reported in volume 54 (Issue ...
... A team of University of Oregon biologists, using fruit ... specific cells, opening a new window on how gene ... While DNA (deoxyribonucleic acid) provides an identical genetic blueprint ... that turn protein molecules on and off in different ...
... is the latest American Chemical Society (ACS) Weekly PressPac ... from ACS, 34 peer-reviewed journals and Chemical & Engineering ... Society as the source for this information. ... melamine-adulterated food , Journal of Agricultural and Food ...
Cached Biology News:The evolutionary foundation of genomic imprinting in lower vertebrates 2New tool isolates RNA within specific cells 2American Chemical Society's Weekly PressPac -- May 13, 2009 2American Chemical Society's Weekly PressPac -- May 13, 2009 3American Chemical Society's Weekly PressPac -- May 13, 2009 4American Chemical Society's Weekly PressPac -- May 13, 2009 5American Chemical Society's Weekly PressPac -- May 13, 2009 6American Chemical Society's Weekly PressPac -- May 13, 2009 7American Chemical Society's Weekly PressPac -- May 13, 2009 8American Chemical Society's Weekly PressPac -- May 13, 2009 9American Chemical Society's Weekly PressPac -- May 13, 2009 10
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Biology Products: